Mittelständische Beteiligungsgesellschaft working together with CENTOGENE to develop biomarkers for the early diagnosis of rare diseases
CENTOGENE AG (CENTOGENE) has been working together for years with local, national, and international partners in developing biomarkers to be used in the early diagnosis of rare diseases. This successful development has been financially supported in the past few years by the Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV), a guarantee institution for medium-sized companies of the state of Mecklenburg-Vorpommern in Germany. “For over six years now we have been working with CENTOGENE on developing their business. As a promoter of regional medium-sized enterprises, we are pleased that such an innovative company is investing in Mecklenburg-Vorpommern”, Managing Director of the MBMV, Dr. Thomas Drews, said enthusiastically.